Table 10 Selective clinical trials of other signaling pathway inhibitors
From: Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Drug | Target | Condition | Status | Phase | NCT identifier |
|---|---|---|---|---|---|
FOXY-5 | WNT-5A receptors | PCa | Completed | 1 | NCT02020291 |
Bevacizumab | VEGF-A | PCa | Completed | 3 | NCT00110214 |
Zibotentan (ZD4054) | ETAR | mCRPC | Completed | 3 | NCT00554229 |
Erdafitinib (JNJ-42756493) | FGFR | DN-PCa | Suspended | 2 | NCT03999515 |
Cetuximab | EGFR | mCRPC | Completed | 2 | NCT00728663 |
Gefitinib (ZD1839) | EGFR | PCa | Completed | 2 | NCT00265070 |
Dovitinib (TKI258) | FGFR, VEGFR, PDGFR | CRPC | Completed | 2 | NCT01741116 |
Sunitinib (SU11248) | VEGFR, PDGFR | mCRPC | Terminated | 3 | NCT00676650 |
Cabozantinib (XL184) | VEGFR, c-MET, c-KIT | mCRPC | Completed | 3 | NCT01605227 |
Masitinib (AB1010) | KIT, PDGFR, FGFR | mCRPC | Completed | 3 | NCT03761225 |
Galunisertib (LY2157299) | TGFβR1 | mCRPC | Recruiting | 2 | NCT02452008 |
M7824 | TGFβ, PD-L1 | Metastatic PCa | Recruiting | 1/2 | NCT04633252 |
Dasatinib (BMS-354825) | SRC, c-KIT | CRPC | Completed | 3 | NCT00744497 |
Saracatinib (AZD0530) | SRC | CRPC | Completed | 2 | NCT00513071 |
Trametinib (GSK1120212) | MEK | mCRPC | Not yet recruiting | 2 | NCT02881242 |
